MiMedx Group (NASDAQ:MDXG) Shares Down 5.9% – Time to Sell?

Shares of MiMedx Group, Inc (NASDAQ:MDXG) were down 5.9% on Thursday . The stock traded as low as $3.55 and last traded at $3.5660. Approximately 623,967 shares traded hands during trading, a decline of 51% from the average daily volume of 1,279,080 shares. The stock had previously closed at $3.79.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on MDXG shares. Cantor Fitzgerald cut their price objective on shares of MiMedx Group from $12.00 to $8.00 and set an “overweight” rating on the stock in a report on Tuesday, February 17th. UBS Group set a $10.00 price objective on shares of MiMedx Group in a report on Monday, February 23rd. Citizens Jmp cut their price objective on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating on the stock in a report on Thursday, April 30th. Citigroup started coverage on shares of MiMedx Group in a report on Monday, February 23rd. They set a “market outperform” rating on the stock. Finally, Wall Street Zen lowered shares of MiMedx Group from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

MiMedx Group Price Performance

The company’s fifty day moving average is $3.81 and its 200 day moving average is $5.35. The company has a quick ratio of 4.81, a current ratio of 5.39 and a debt-to-equity ratio of 0.07. The stock has a market cap of $537.70 million, a PE ratio of 18.05 and a beta of 1.46.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings results on Wednesday, April 29th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.02. MiMedx Group had a net margin of 7.88% and a return on equity of 21.03%. The firm had revenue of $58.99 million for the quarter, compared to analyst estimates of $65.80 million. As a group, sell-side analysts anticipate that MiMedx Group, Inc will post -0.01 earnings per share for the current fiscal year.

Institutional Trading of MiMedx Group

Hedge funds have recently made changes to their positions in the company. First Light Asset Management LLC raised its stake in shares of MiMedx Group by 89.5% during the third quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company’s stock valued at $25,498,000 after purchasing an additional 1,725,458 shares during the period. Hussman Strategic Advisors Inc. purchased a new stake in shares of MiMedx Group during the third quarter valued at approximately $1,759,000. Allspring Global Investments Holdings LLC raised its stake in shares of MiMedx Group by 433.2% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 289,199 shares of the company’s stock valued at $1,958,000 after purchasing an additional 234,958 shares during the period. Vanguard Group Inc. raised its stake in shares of MiMedx Group by 5.6% during the fourth quarter. Vanguard Group Inc. now owns 7,184,262 shares of the company’s stock valued at $48,637,000 after purchasing an additional 382,623 shares during the period. Finally, SG Americas Securities LLC raised its stake in shares of MiMedx Group by 16.1% during the fourth quarter. SG Americas Securities LLC now owns 188,045 shares of the company’s stock valued at $1,273,000 after purchasing an additional 26,085 shares during the period. Hedge funds and other institutional investors own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.